share_log

Pfizer | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Pfizer | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

辉瑞 | S-8：员工福利计划证券登记
美股sec公告 ·  05/09 09:03
Moomoo AI 已提取核心信息
Pfizer Inc. has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on May 9, 2024, to register an additional 320 million shares of common stock under its Amended and Restated 2019 Stock Plan. This move follows the approval by Pfizer's shareholders at the Annual Meeting on April 25, 2024, to authorize the additional shares for issuance under the Plan. The registration statement incorporates by reference the contents of Pfizer’s effective registration statements on Form S-8 filed previously with the SEC. The documents required for the registration statement will be delivered to participants in the Plan as specified by the SEC rules and are available upon request. The registration statement includes references to Pfizer's recent financial reports and other filings with the SEC, which are incorporated by reference and provide updated information to the SEC and investors.
Pfizer Inc. has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on May 9, 2024, to register an additional 320 million shares of common stock under its Amended and Restated 2019 Stock Plan. This move follows the approval by Pfizer's shareholders at the Annual Meeting on April 25, 2024, to authorize the additional shares for issuance under the Plan. The registration statement incorporates by reference the contents of Pfizer’s effective registration statements on Form S-8 filed previously with the SEC. The documents required for the registration statement will be delivered to participants in the Plan as specified by the SEC rules and are available upon request. The registration statement includes references to Pfizer's recent financial reports and other filings with the SEC, which are incorporated by reference and provide updated information to the SEC and investors.
辉瑞公司已于2024年5月9日向美国证券交易委员会（SEC）提交了注册声明，要求根据其经修订和重述的2019年股票计划再注册3.2亿股普通股。此举是在辉瑞股东在2024年4月25日的年会上批准根据该计划增发股份之后采取的。注册声明以引用方式纳入了辉瑞先前向美国证券交易委员会提交的S-8表格上的有效注册声明的内容。注册声明所需的文件将按照美国证券交易委员会规则的规定交付给计划的参与者，并可应要求提供。注册声明包括对辉瑞最近向美国证券交易委员会提交的财务报告和其他文件的引用，这些文件以引用方式纳入，并向美国证券交易委员会和投资者提供最新信息。
辉瑞公司已于2024年5月9日向美国证券交易委员会（SEC）提交了注册声明，要求根据其经修订和重述的2019年股票计划再注册3.2亿股普通股。此举是在辉瑞股东在2024年4月25日的年会上批准根据该计划增发股份之后采取的。注册声明以引用方式纳入了辉瑞先前向美国证券交易委员会提交的S-8表格上的有效注册声明的内容。注册声明所需的文件将按照美国证券交易委员会规则的规定交付给计划的参与者，并可应要求提供。注册声明包括对辉瑞最近向美国证券交易委员会提交的财务报告和其他文件的引用，这些文件以引用方式纳入，并向美国证券交易委员会和投资者提供最新信息。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息